Novartis cut its mid-term sales growth target as blockbuster patents expire Nov 19, 2026 · Cris Tolomia Peak sales guidance is higher for Kesimpta, Scemblix and Leqvio, and Novartis said its core margin is on track to return to 40% or higher by 2029 Read more »